References
- Indian Council for Medical Research. Population based cancer registry. Available from URL: http://www.icmr.nic.in[accessed May 1, 2007]
- Druker B J, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gattermann N, Deininger, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med 2006; 355: 2408–2417
- Hasford J, Pfirrmann M, Hehlmann R, Allan N C, Baccarani M, Kluin-Nelemans, et al. (Writing Committee for the Collaborative CML Prognostic Factors Project Group). A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850–858
- Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, nonrandomized study. J Assoc Physicians India 2005; 53: 291–295
- Usman M, Syed N N, Kakepoto G N, Adil S N, Khurshid N. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of sokal score, age and disease duration in predicting the hematological and cytogenetic response. J Assoc Physicians India 2007; 55: 103–107
- Jacob A, Bapsy P P, Govind B K, Lokanatha D. Imatinib mesylate in newly diagnosed patients with chronic myeloid leukemia. ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25(18S)17521
- Zeba A, Javaid I, Mohammed A, Sarah S. Treatment of chroinic myeloid leukemia in the imatinib era-perspective from a developing country. Cancer 2007; 109: 1138–1145
- Cortes J. Natural history and staging of chronic myeloid leukemia. Hematol Oncol Clin N Am 2004; 18: 569–584
- Kantarjian H M, Sawyer C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic response to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med 2002; 346: 645–652
- Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic phase chronic myeloid leukemia. Blood 2004; 103: 2284–2290
- O'Brien, Guilhot F, Larson R A, Gathmann I A, Baccarani M, Cervantes F, Cornellisen J J, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
- Kantarjian H, Cortes J, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon alpha. Blood 2004; 104: 1979–1988
- Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005; 103: 1659–1669
- Hughes T. ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. ASH Education Program Book Hematol 2006; 213
- Radich J P, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794–2799
- White D L, Saunders V A, Dang P, Engler J, Zannettino A C, Cambareri A C, et al. OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib; reduced OCT-1 activity is the cause of low in-vitro sensitivity to imatinib. Blood 2006; 108: 697–704
- Thomas J, Wang L, Clark R E, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739–3745
- Baccarrani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European leukemia network. Blood 2006; 108: 1809–1822